Physician
The Oncology Institute Ca, a Professional Corporation
The Oncology Institute Ca, a Professional Corporation was paid $8.17M by Medicaid between Jan 2018 and Dec 2024, across 61 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 28% of everything it billed.
33Billing provider infoTHE ONCOLOGY INSTITUTE CA, A PROFESSIONAL CORPORATION
DOWNEY, CA 90241
DOWNEY, CA 90241
33aNPI1275651515assigned 03/26/2007
33bProvider typeMedical Oncology Physician
28Total paid$8.17M
24GClaims372,680
24DCodes billed61
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Medical Oncology Physician providers in California
Rank by total paid#2 of 33
Median peer was paid$29K
This provider vs. median279×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 21,899 | $594K | |
| 2019 | 32,305 | $1.16M | |
| 2020 | 36,256 | $1.24M | |
| 2021 | 51,626 | $1.03M | |
| 2022 | 72,423 | $1.69M | |
| 2023 | 86,541 | $1.55M | |
| 2024incomplete | 71,630 | $914K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 28% | 111,799 | 105,943 | $2.25M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 16% | 32,720 | 22,612 | $1.31M |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 11% | 14,223 | 9,500 | $932K |
| J9271 | Injection, pembrolizumab, 1 mg | 7.6% | 165 | 129 | $625K |
| 96367 | 6.3% | 32,240 | 22,073 | $515K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 4.7% | 13,218 | 8,596 | $384K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4.3% | 39,552 | 38,871 | $348K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 3.1% | 11,846 | 11,822 | $250K |
| 99223 | Prolong inpt eval add15 m | 2.5% | 4,530 | 4,357 | $206K |
| 99232 | Hospital visit by a doctor, follow-up daySubsequent hospital care, per day, moderate complexity | 2.2% | 9,521 | 3,549 | $180K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.0% | 10,500 | 6,806 | $166K |
| 99233 | Hospital visit by a doctor, follow-up day (complex)Prolong inpt eval add15 m | 1.9% | 7,281 | 2,681 | $155K |
49 more codes
| 99215 | Doctor's office visit, returning patient (complex) | 1.5% | 6,190 | $123K |
| 99205 | Prolong outpt/office vis | 1.3% | 3,976 | $108K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.3% | 5,188 | $105K |
| 96415 | <1% | 7,689 | $76K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 117 | $64K |
| 99442 | <1% | 7,881 | $63K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,620 | $56K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,874 | $32K |
| 96417 | <1% | 4,492 | $31K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 861 | $30K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,862 | $22K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 6,781 | $20K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,472 | $20K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 642 | $17K |
| G6012 | Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 mev | <1% | 122 | $14K |
| 99000 | <1% | 8,780 | $8K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 715 | $8K |
| 77427 | <1% | 116 | $7K | |
| 99443 | <1% | 1,051 | $5K | |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | <1% | 78 | $4K |
| J1750 | Injection, iron dextran, 50 mg | <1% | 325 | $4K |
| 99441 | <1% | 951 | $4K | |
| 77336 | <1% | 124 | $4K | |
| 96127 | <1% | 1,433 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 790 | $3K |
| 99255 | <1% | 112 | $3K | |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 217 | $3K |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 1,985 | $2K |
| 96402 | <1% | 527 | $2K | |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 40 | $2K |
| 96368 | <1% | 400 | $1K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 54 | $817.81 |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 31 | $777.20 |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | <1% | 88 | $490.00 |
| 99221 | <1% | 46 | $466.71 | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 33 | $437.49 |
| 36591 | <1% | 868 | $422.75 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 39 | $116.80 |
| 96401 | <1% | 108 | $84.10 | |
| 80053 | Comprehensive metabolic panel | <1% | 517 | $73.86 |
| 77417 | <1% | 22 | $73.74 | |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 30 | $62.15 |
| J3490 | Unclassified drugs | <1% | 77 | $39.51 |
| G0008 | Administration of influenza virus vaccine | <1% | 17 | $36.00 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 676 | $28.20 |
| 96523 | <1% | 16 | $23.61 | |
| 90688 | 0% | 16 | $0.00 | |
| 82728 | 0% | 14 | $0.00 | |
| J9267 | Injection, paclitaxel, 1 mg | 0% | 22 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPODNOS, YALE (CMO, OWNER, PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| The Oncology Institute Ca, a Professional Corporation | Tucson, AZ | $96K |
| The Oncology Institute Ca, a Professional Corporation | Las Vegas, NV | $46K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.